Business
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
Preclinical Data Presented at Frontiers in Cancer Immunotherapy 2022 Shows Potent Antibody-Dependent Cellular Cytotoxicity with Afucosylated Plant-Made
About this update from Ibio, Inc.
[{"type":"text","content":"Preclinical Data Presented at Frontiers in Cancer Immunotherapy 2022 Shows Potent Antibody-Dependent Cellular Cytotoxicity with Afucosylated Plant-Made Molecule\nNEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, announced today a poster presentation on IBIO-101, the Company's monoclonal antibody candidate for the treatment of solid tumors. The presentation will take place at Frontiers in Cancer Immunotherapy 2022 by the New York Academy of Sciences from May 9-11. Preclinical evaluation of IBIO-101, produced with iBio’s FastPharming and GlycaneeringSM Systems, showed equivalent efficacy and potency compared with this IL-2 sparing anti-CD25 antibody made using traditional mammalian cell culture methods (RTX-003 from RubrYc Therapeutics, Inc.). Additionally, iBio’s proprietary afucosylation technology enabled the engineering of a more potent version without incremental intellectual property access costs. The Company now plans to advance its Glycaneered anti-CD25 monoclonal antibody for the depletion of regulatory T cells (“Tregs”) to the clinic next year. Dillon Phan, PhD, iBio’s Vice President and Head of Early Research and Development, will present the poster, titled \"Plant-Based Expression and Glyco-Engineering of Novel IL-2 Signaling Permissive Anti-CD25 Antibodies for Effective Treg Depletion in Cancer\", which highlights: A CD25 epitope-survey using a novel artificial intelligence/machine learning platform to identify one epitope and corresponding antibodies with particularly high antibody-dependent cellular cytotoxicity (“ADCC”) activity.The production of a Glycaneered version of IBIO-101, which significantly increased effector function resulting from afucosylation using a deltaXT/FT N. benthamiana host compared with a fucoslyated form of the molecule.Binding of IBIO-101 specifically to CD25+ cancerous cells with high affinity.Preserved IL-2 signaling to effector T cells via pSTAT5.Potent ADCC activity in killing cancer cells. More information on cancer drug discovery and development with plants may be accessed in an article on the topic here. About iBio, Inc. iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologi...